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Although the diagnostic utility of thallium-20l myo-
cardial imaging after dipyridamole infusion is well es-
tablished, the intravenous form of the drug is not yet
commercially available in North America. Fifty patients
referred for coronary angiography were prospectively
studied. Within a 2 week period, each patient underwent
cardiac catheterizatlon and thallium-20t myocardial im-
aging after both oral and intravenous dipyridamole
administration. For the oral protocol, patients were ran-
domly assigned to treatment with either 200 or 400 mg
of dipyridamole in tablet form. Coronary artery stenoses
of 70% or greater were considered significant.
For the 2S patients who received a 200 mg oral dose
of dipyridamole, the scintigraphic study showed perfu-
sion defects in 6S% of patients with significant coronary
artery disease after the oral dose and in 8S% of patients
after the intravenous dose. For the 2S patients who re-
Thallium-20l myocardial imaging after exercise stress test-
ing is widely accepted for establishing the diagnosis and
prognosis of coronary artery disease and evaluating the
hemodynamic significance of documented coronary stenoses
(1-4). However, it is essential that the patient achieve an
adequate level of exercise so that blood flow in normal
coronary arteries increases at least twofold in comparison
with that in stenosed arteries, thus creating the diagnostic
inhomogeneous distribution of thallium-201 on the myo-
cardial scintigram.
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ceived a 400 mg oral dose, the sensitivity of the scinti-
gram was 84% after the oral dose and 79% after the
intravenous dose. Except for headache and nausea, side
effectswere lesssevere and less frequent with oral (either
200 or 400 mg) than with intravenous dipyridamole.
Because of the delayed and variable absorption of di-
pyridamole tablets, the oral studies required a longer
period of medical supervision (4S to 60 minutes), and
aminophylline was empirically administered after com-
pletion of the first set of thallium-20l images.
His concluded from this study that thallium-2Ot myo-
cardial imaging after coronary vasodilation with a 400
mg oral dose of dipyridamole is a safe, widely available
and reliable alternative for the evaluation of coronary
artery disease in patients unable to achieve an adequate
exercise level on stress testing.
(J Am Coli CardioI1986;8:76-83)
Maximal exercise stress testing frequently cannot be
achieved for various reasons. Musculoskeletal abnormali-
ties, peripheral vascular disease, chronic lung disease or
early onset of arrhythmias or chest pain during the exercise
protocol can limit the patient's ability to perform an adequate
test. This is particularly significant for institutions treating
a large geriatric population. For a variety of reasons, patients
are often taking beta-adrenergic blocking agents or calcium
channel blockers and the target heart rate is thus not attained
during exercise testing. Although the diagnostic utility of
thallium-20l myocardial imaging after coronary vasodila-
tion with a dipyridamole infusion is well established (5-10),
the intravenous form of this drug is not currently commer-
cially available in North America. Its use is restricted to
research protocols, whereas the oral form of dipyridamole
is widely used clinically. Oral dipyridamole has been eval-
uated for thallium-20l myocardial imaging in very few stud-
ies (11-13) and comparison with intravenous dipyridamole
was done in a small number of patients.
We prospectively studied 50 patients referred for coro-
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Figure 1. Schematic representation of the intra-
venous dipyridamole protocol. Dipyridamole was
administered at a rate of 0.142 mg/kg per min for
a periodof 4 minutes. i.v. = intravenous; 201TL =
thallium-20I.
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nary angiography to evaluate the diagnostic accuracy of
thallium-201 myocardial imaging after administration of both
intravenous and oral dipyridamole. We also compared myo-
cardial imaging after two oral dose regimens (200 and 400
mg) to determine the optimal dipyridamole dose for imaging
purposes.
Methods
Study patients. Thallium-201 myocardial scintigraphic
studies after both intravenous and oral dipyridamole admin-
istration were performed in 50 patients referred for coronary
angiography for the evaluation of chest pain. In each case,
the oral and intravenous studies were performed at I week
intervals and within 3 weeks of coronary angiography and
left ventriculography. Patients were randomly assigned to
one of two groups with respect to the oral dose of dipyr-
idamole (either 200 or 400 mg). Written informed consent
was obtained from each patient, and the protocol was ap-
proved by the ethics committee of our institution.
Patients with unstable angina, severe arrhythmias, recent
« 6 weeks) myocardial infarction, overt congestive heart
failure, signficant valvular heart disease or severe pulmo-
nary disease were excluded from the study. Cardiovascular
drugs and those containing methylxanthines were discon-
tinued 24 hours before the study.
Cardiac catheterization. All patients underwent coro-
nary angiography and left ventriculography using the Jud-
kins technique with multiple views of the right and left
coronary arteries. Coronary angiograms were interpreted by
two independent observers who did not know the results of
the thallium-20l myocardial studies. Differences in inter-
pretation were resolved by consensus. Significant coronary
artery stenosis was determined by quantitative analysis and
was defined as a 70% or greater reduction in luminal di-
ameter of one or more major coronary arteries.
Dipyridamole infusion protocol. Patients were in-
structed to fast after midnight and told specifically to avoid
coffee and tea (which contain theophylline, a dipyridamole
antagonist). With the patient in the supine position, baseline
heart rate and blood pressure were recorded. The electro-
cardiogram was continuously monitored using lead II. An
intravenous line with normal saline solution was installed
with a 20 gauge cannula in an antecubital vein. Dipyrida-
mole was infused at a rate of 0.142 mg/kg per min over 4
minutes and the vital signs and electrocardiogram were re-
corded every minute (Fig. 1). After the infusion, the patient
stood up and walked in place for 2 to 3 minutes. At that
point, 2.0 mCi of thallium-20l was injected as a compact
bolus into the cannula followed by a flushing volume of 10
ml of normal saline solution. The patient continued walking
in place for 2 minutes, then lay down under the scintillation
camera and myocardial imaging began. During each study,
aminophylline, 125 mg, was available to reverse adverse
effects of dipyridamole, if necessary. All side effects re-
ported by the patient were duly recorded as slight, moderate
or severe.
Oral dipyridamole administration protocol. Instruc-
tions to the patient, preparation and baseline monitoring
were identical to those described for the intravenous dipyr-
idamole protocol. After the administration of either the 200
or the 400 mg dose of dipyridamole according to random-
ization, the patient lay supine for 45 to 60 minutes and the
vital signs and electrocardiogram were monitored and re-
corded every IO minutes (Fig. 2). The patient then stood
up, walked in place for 2 to 3 minutes and 2.0 mCi of
thallium-20l was injected. Thallium-20l was injected ear-
lier in cases where clinical symptoms such as angina or
significant hemodynamic changes necessitating aminophyl-
line administration occurred before the usual delay. Thal-
lium-201 was injected an average of 54 minutes after inges-
tion of oral dipyridamole. If there were no side effects or
initial ~.Ia~d
imaging Imaging[----11----1
1/
Figure 2. Oral dipyridamole protocol. Patients re-
ceived either 200 or 400 mg of dipyridamole (100
mg tablets). Abbreviations as in Figure I.
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changes in hemodynamic variables at 45 minutes , thallium
injection was delayed until the occurrence of the event or
at 60 minutes , whichever came first. The sequence of di-
pyridamole administration (that is, first oral, then intrave-
nous and vice versa) was randomized among the patients.
Thallium-201 myocardial imaging and analysis.
Myocardial planar imaging started 5 minutes after thallium-
201 injection with a small field of view mobile scintillation
camera using a low energy all-purpose parallel-hole colli-
mator. The first image acquired was a 45° left anterior oblique
view followed by the anterior and 70° left anterior oblique
projections. Eight minute images (approximately 350,000
counts) were acquired for each view (initial and delayed
images) with the photopeak set at 80 keY with a 20% win-
dow. In all cases, redistribution images were obtained 4
hours later and the patient was instructed to eat only lightly
during that time interval. Care was taken to position the
patient identically for the initial and redistribution studies.
All myocardial scintigraphic studies were analyzed by
three experienced observers without prior knowledge of the
patient's history, electrocardiogram, coronary anatomy or
the mode of administration of dipyridamole (oral or intra-
venous) . Disagreements in interpretation were resolved by
consensus. Thallium-20l activity in each segment was sub-
jectively graded by each observer on a scale from 0 (no
activity) to 2 (normal activity) , as previously described (14).
For each scintigraphic study, the images were displayed side
by side and were available in three presentations: an analog
image , a black and white display with a 15% uniform back-
ground subtraction and a color display . Furthermore , quan-
titative analysis was performed for heart to lung ratios and
segmental activity profiles of opposing myocardial walls for
each view (for both the initial and redistribution studies).
Interpretation was based primarily on analog image and
segmental activity profiles after uniform background sub-
traction , using other displays only in equivocal cases. Be-
cause the normal values with dipyridamole thallium-201
imaging have not been established, we did not use quan-
titation of thallium-201 uptake and washout rate analysis.
An abnormality on initial myocardial imaging was defined
as an area of absent or decreased thallium activity. Because
the end point was the diagnosis of coronary artery disease ,
a fixed defect was also considered positive.
Table 1. Characteristics of the StudyPatient s
Statistical analysis. The sensitivity and specificity of
the dipyridamole thallium-20 I scintigraphic studies were
defined as follows: sensitivity = true positive tests x 100
divided by the sum of true positive plus false negative tests;
specificity = true negative tests x 100 divided by the sum
of true negative plus false positive tests. All results are
expressed as mean ± SD. Changes in hemodynamic vari-
ables were evaluated using a paired Student's t test.
Results
Patient characteristics (Table I). There were 35 men
and 15 women whose ages ranged from 34 to 70 years (mean
54). The 50 patients were categorized into group I (n =
25; oral dipyridamole, 200 mg) and group II (n ::= 25; oral
dipyridamole, 400 mg). Twenty patients in group I (80%)
had significant coronary artery disease; 10 of these had
single vessel disease, 8 had double vessel disease and 2
triple vessel disease. The distribution and degree of coronary
artery involvement were similar for the patients in group II
except for a slightly smaller number of cases of double
vessel disease (six instead of eight). There were no cases
of left main coronary artery disease.
Hemodynamic response to oral and intravenous di-
pyridamole. Three hemodynamic variables were evaluated:
the heart rate and systolic and diastolic blood pressure re-
sponses for each group. There were significant changes (p
< 0.001) in those three variables over time after adminis-
tration of oral (both 200 and 400 mg) and intravenous di-
pyridamole. The mean heart rate increase was 7 ± 6, 11
± 9 and 13 ± 5 beats/min for the 200 and 400 mg oral
dose and intravenous studies , respectively . The difference
in heart rate increase was significant between intravenous
and 200 mg studies (p < 0.005) and between 400 and 200
mg studies (p < 0.005) but not between intravenous and
400 mg protocols (p ::= 0.2). The mean systolic blood pres-
sure decrease was 7 ± 5, 7 ± 7 and 7 ± 5 mm Hg and
the mean diastolic blood pressure decrease was 6 ± 6, 7
± 5 and 7 ± 6 mm Hg for the 200 and 400 mg oral dose
and intravenous studies , respectively; the difference was not
statistically significant among the groups .
Adverse effects (Fig. 3). Serious complications such as
arrhythmia, myocardial infarction or death did not occur .
No Significant
Significant CAD
Sex (no.): CAD One Two Three
Group No. Mean Age (yr) (range) (no.) No. Vessel Vessels Vessels
1 (200 mg) 25 F (8): 55.4 (44 to 69) 5 (2F, 3M) 20 10 8 2
M (17): 52.8 (43 to 63)
11(400 mg) 25 F (7): 52.7 (39 to 70) 6 (4F, 2M) 19 11 6 2
M (18): 55.2 (34 to 66)
CAD = coronary artery disease; F = female; M = male.
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Figure 3. Incidence of adverse effects in (A) 39
patientswith hemodynamically significant coronary
arterydiseaseand (B) 11 patientswith normalcoro-
nary anatomy.
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Headache was slightly more frequent with oral dipyridamole
and there was a similar incidence of nausea with the intra-
venous and oral forms . All other symptoms were more fre-
quent with the intravenous form. Symptoms as graded by
the patients were judged to be more intense with intravenous
than with oral dipyridamole in more than 85% of cases .
With the oral form, adverse effects usually occurred between
30 and 75 minutes after drug ingestion, except for nausea
and epigastric discomfort, which sometimes appear earlier
(only one patient had these latter symptoms later than 25
minutes after ingestion).
Aminophylline , 125 mg intravenously , was administered
tofive patients specifically for chest pain and reliefoccurred
within 5 minutes. Three of these patients had significant
coronary artery disease (single , double and triple vessel
disease, respectively) but two patients had no significant
lesions. All five patients required aminophylline after the
intravenous administration of dipyridamole but only three
after the oral dose (two patients without significant coronary
artery disease and one with triple vessel disease). Of these
three patients , one received 400 and two received 200 mg
of oral dipyridamole. A sixth patient who had normal coro-
nary anatomy required the administration of aminophylline
for nausea and dizziness after intravenous dipyridamole. In
all of these cases , aminophylline was injected when the
imaging began, that is, at least 5 minutes after the injection
of thallium- 20I. This was done in order not to interfere with
initial perfusion imaging .
As a precaution we empirically administered amino-
phylline to all patients after completion of the first set of
myocardial scintigraphic studies to avoid potential problems
in patients who might have a delayed peak level or clearance
of oral dipyridamole.
Sensitivity and specificity of thallium-20t images (Ta-
ble 2). Group I (oral dipyridamole, 200 mg). In this
group, thallium-201 imaging with dipyridamole showed one
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Table 2. Sensitivity and Specificity of Thallium-201
Scintigraphy With Intravenous and Oral Dipyridamole
Administration for Detection of Significant Coronary
Artery Disease
or more perfusion defects in the initial images in 13 of the
20 patients with coronary artery disease for a sensitivity of
65% with the 200 mg oral study and 17 of the 20 patients
for a sensitivity of 85% with the intravenous study. Of the
13 and 17 patients (oral and intravenous doses, respectively)
with coronary artery disease and one or more perfusion
defects, 12 and 16 demonstrated partial or complete redis-
tribution in at least one myocardial segment after oral and
intravenous dipyridamole, respectively. There were seven
false negative tests with the 200 mg oral study; four patients
had single vessel disease (three tests were positive on the
intravenous study) and three had double vessel disease (one
*0.142 mg/kg per min for 4 minutes.
Group I
positive test on the intravenous study). There were three
false negative results with the intravenous study; all three
patients had single vessel disease (one test was positive on
the oral study). For both oral and intravenous dipyridamole
studies there were no false positive tests (five patients with
normal coronary anatomy) for a specificity of 100%. Two
patients had a history of prior myocardial infarction local-
ized to the anterior and septal walls. In one of these patients
both oral and intravenous studies demonstrated a fixed defect
in the infarcted area. In the other patient, in addition to a
fixed anterior wall defect, a transient septal defect was dem-
onstrated by both studies.
Group lJ (oral dipyridamole, 400 mg). In this group,
thallium-201 imaging with dipyridamole detected 16 of 19
patients with coronary artery disease for a sensitivity of 84%
with the 400 mg oral study, and 15 of 19 patients for a
Figure 4. Initial (left) and delayed (right) thallium-201 images
after (A) oral dipyridamole, 400 mg and (B) intravenous dipyr-
idamole administration in a patient with an isolated subtotal ste-
nosis of the proximal left anterior descending artery. Note the
transient perfusion defects of the anterior and septal walls (arrows)
in both the oral and intravenous studies. ANT = anterior view;
LAO = left anterior oblique view.
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sensitivity of 79% with the intravenous test. Of these 16
and 15 patients (oral and intravenous dose, respectively)
with one or more perfusion defects on initial imaging, 15
and 14 demonstrated partial or complete redistribution in at
least one myocardial segment after oral and intravenous
dipyridamole, respectively. There were three false negative
tests with the 400 mg oral study and all three patients had
single vessel disease (one test was positive with the intra-
venous study). There were four false negative tests with the
intravenous study and all four patients had single vessel
disease (two tests were positive on the oral study). There
were no false positive tests with the oral dose (six patients
with no significant coronary artery disease) for a specificity
of 100% and one false positive test on the intravenous study
for a specificity of 86%. Two patients had a prior myocardial
infarction. In one of these patients, with two significant
coronary stenoses, both oral and intravenous studies dem-
onstrated an anteroseptal infarction with a transient perfu-
sion defect in the area supplied by the other stenosed coro-
nary artery. In the other patient, the intravenous study
demonstrated a fixed anterior segmental defect whereas the
400 mg oral study, in addition to the infarcted area, showed
partial redistribution involving the apex.
Evaluation of the diagnostic quality of scintigraphic
studies. When the results of oral and intravenous studies
were congruent (Fig. 4 and 5) in the same patient, the three
Figure 5. Initial (left) and delayed (right) thallium-20l images
after (A) oral dipyridamole, 400 mg and (8) intravenous dipyr-
idamole in a patient with an occluded proximal right coronary
artery. Note the transient perfusion defect of the inferior wall
(arrows) in both the oral and intravenous studies. Abbreviations
as in Figure 4.
A
observers attempted to subjectively evaluate the diagnostic
quality of both sets of scintigraphic studies in the same
patient without knowledge of the type of dipyridamole
administration. The main criteria for the comparison of both
studies were the degree of contrast between hypoperfused
and normally perfused myocardial segments and the sub-
jective evaluation of the extent of the decreased perfusion.
The oral and intravenous studies were judged similar in
diagnostic quality in 70% of patients in group I (200 mg)
and in 67% of patients in group II (400 mg). The intravenous
study was superior to the oral study in 30% of patients in
group I and in 8% of patients in group II. The oral study
was never better than the intravenous study in group I but
was judged superior to the intravenous tests in 25% of pa-
tients in group II.
Discussion
Noninvasive assessment of coronary stenoses by thal-
lium-201 myocardial imaging during pharmacologic coro-
nary vasodilation with intravenous dipyridamole is a rec-
ognized diagnostic procedure in clinical practice. Unfor-
tunately, because the intravenous form of the drug is not
yet commercially available, its use has been limited to re-
search protocols. Oral administration of dipyridamole would
be preferable for this purpose. There have been only two
previous reports (11,12) on the use of oral dipyridamole
and comparison with its intravenous form for thallium-201
myocardial imaging. Despite the small number of patients
evaluated (a total of 22 patients for both studies with 200
and 300 mg), the authors showed good correlation with
intravenous dipyridamole. We have compared two oral dose
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regimens, 200 and 400 mg. The 400 mg oral dose was
empirically chosen to evaluate the safety and reliability of
high dose oral dipyridamole and thereby improve sensitivity
of thallium-20l myocardial imaging.
Oral versus intravenous dipyridamole. In our study
of 50 patients, the diagnostic yield of thallium-201 myo-
cardial imaging with 400 mg of oral dipyridamole (sensi-
tivity 84%) is equal to that with the intravenous form (sen-
sitivity 79%, not statistically different). Those results are
significantly better than results with the 200 mg oral dose
(sensitivity 65%). This difference in detection of myocardial
ischemia is probably dose related. Although the decrease in
systolic and diastolic blood pressure was similar with both
200 and 400 mg, the heart rate increase was more important
and side effects were slightly more frequent and more in-
tense with the 400 mg oral dose although less than with
intravenous dipyridamole. The relative degree of initial
myocardial hypoperfusion is essential for diagnostic im-
aging purposes. The diagnostic quality of the images ob-
tained with the 400 mg dose was judged superior to that
obtained with intravenous dipyridamole in 25% of cases.
The reverse was true in only 8% of cases.
Advantages of oral dipyridamole. The oral preparation
offers advantages in comparison with the intravenous dose.
It is commercially available and easy to obtain in contrast
to the intravenous form, which can be used only on an
experimental basis, thus limiting its widespread use. Except
for headache and nausea, side effects were less severe and
less frequent with oral (either 200 or 400 mg) administration
than with the intravenous dose. The time to onset of side
effects including chest pain varied from 30 to 75 minutes
after the oral administration of dipyridamole. The chest pain
was promptly resolved by intravenous injection of amino-
phylline in every patient. There were no ventricular ar-
rhythmias or evidence of myocardial infarction secondary
to the administration of oral dipyridamole. However, no
patient with recent myocardial infarction or unstable angina
was included in this study.
Disadvantages of oral dipyridamole. There are also
some disadvantages to the use of the oral drug. It needs a
longer period of medical supervision (up to 60 minutes
compared with 5 to 10 minutes for the intravenous protocol).
Because of variable absorption of the dipyridamole tablets,
neither time of onset nor time to peak blood levels of the
medication can be determined precisely (15,16). The use
of an oral dipyridamole suspension may allow peak drug
levels to be attained more quickly but possibly at the expense
of an increased incidence and a more rapid onset of side
effects (17). Because of these unpredictable blood levels of
the drug, we empirically gave the patients intravenous ami-
nophylline (75 mg) after completion of the initial phase of
thallium-201 imaging. On the basis of two previous studies
(11,12), we administered fixed doses of oral dipyridamole
and further studies are needed to determine the optimal oral
dose, possibly on a milligram per kilogram body weight
basis as we do with intravenous studies.
Limitations of the study. There are some limitations to
our study. Unfortunately, measurement of serum dipyrid-
amole levels was not available at the time of the study. It
would have been useful to compare the blood levels for both
oral and intravenous dipyridamole at the time of thallium-
20 I injection and this for each patient. A recent study (17)
found similar serum drug levels with a 300 mg oral dose
suspension and intravenous dipyridamole. From these data,
we can assume that with the 400 mg oral dose, blood levels
of dipyridamole at the time of thallium-20l injection are at
least equal to those obtained after 4 minutes of dipyridamole
infusion. This might explain the similar diagnostic yield of
both forms of dipyridamole administration. However, it has
to be confirmed by serum dipyridamole assay because the
previous study (17) used a 300 mg oral suspension, which
has different pharmacokinetics from the tablet form. Thal-
lium-20l washout curves were not generated in our study
because normal values with dipyridamole have not been
established. Furthermore, recent data (18) suggest that there
is a significant individual variation in regional thallium-201
washout; therefore, the clearance of thallium-20 I would not
be reproducible with intravenous dipyridamole. This needs
further investigation. It is important to note that our patients
were a selected group in that they were all initially referred
for coronary angiography for clinically suspected coronary
artery disease; therefore our statistics do not reflect the sen-
sitivity and specificity of this test done in the general pop-
ulation. The number of patients with no coronary artery
disease (five in group I and six in group II) is also too small
to draw conclusions on the true specificity of the test.
Conclusion. Despite the limitations mentioned, we be-
lieve that thallium-201 myocardial imaging during phar-
macologically induced coronary vasodilation with a 400 mg
oral dose of dipyridamole is a safe, available and reliable
alternative for the evaluation of coronary artery disease in
patients unable to achieve adequate exercise levels. Even
when the intravenous form of the drug will be commercially
available, oral dipyridamole may still prove useful consid-
ering the lower incidence and severity of side effects.
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